Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
Revenue of Silk Road Medical, Inc (SILK)
Revenue in 2023 (TTM): $177.13 M
According to Silk Road Medical, Inc's latest financial reports the company's current revenue (TTM) is $177.13 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Silk Road Medical, Inc
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $177.13 M | $127.09 M | $-45,080,000 | $-55,743,000 | $-55,743,000 |
| 2022 | $138.64 M | $100.76 M | $-46,744,000 | $-55,010,000 | $-58,016,000 |
| 2021 | $101.48 M | $76.03 M | $-45,549,000 | $-49,811,000 | $-50,387,000 |
| 2020 | $75.23 M | $53.94 M | $-41,468,000 | $-47,365,000 | $-50,385,000 |
| 2019 | $63.35 M | $47.43 M | $-46,169,000 | $-52,415,000 | $-56,073,000 |
| 2018 | $34.56 M | $23.68 M | $-32,752,000 | $-37,630,000 | $-37,629,000 |
| 2017 | $14.26 M | $9.13 M | $-18,245,160 | $-19,356,000 | $-19,356,000 |